Lizhou Zhang

Lizhou Zhang

Auto-generated profile, based on publicly available information

Lizhou Zhang

Division of Infectious Disease, Boston Children’s Hospital

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
LZLizhou Zhang
Lizhou Zhang
KMKunal R. More
Kunal R. More
AOAmrita Ojha
Amrita Ojha
CJCody B. Jackson
Cody B. Jackson
BQBrian D. Quinlan
Brian D. Quinlan
HCHyeryun Choe
Hyeryun Choe
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4 °C. Moreover, Pfizer-BioNTech’s 5′ UTR and Moderna’s 3′ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.

27 July 2010 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
LZLi-Zhou Zhang
Li-Zhou Zhang
TZTian-Chen Zhang
Tian-Chen Zhang
FPFaming Pan
Faming Pan
ZZZhenhua Zhang
Zhenhua Zhang
XLXu Li
Xu Li

23 October 2025 in Journal of Virology
Verified
Journal Article
Open access
LZLizhou Zhang
Lizhou Zhang
BSByoung-Shik Shim
Byoung-Shik Shim
CKClaire Kitzmiller
Claire Kitzmiller
YKYoung-Chan Kwon
Young-Chan Kwon
ARAudrey Stéphanie Richard
Audrey Stéphanie Richard
HCHyeryun Choe
Hyeryun Choe
Many enveloped viruses engage phosphatidylserine (PS) receptors to enter cells, a phenomenon known as “apoptotic mimicry.” We previously reported that Zika virus (ZIKV), but not closely related West Nile virus (WNV) or dengue virus (DENV), utilized AXL to infect cells because only ZIKV could bind the AXL ligand GAS6, a PS-binding protein. In this study, we investigated the mechanisms underlying the differential ability of these viruses to bind GAS6. Although immature virions expose larger patches of the viral membrane than do mature ones, our data show that virion maturity levels did not contribute to GAS6 binding. Surprisingly, while ZIKV contains PS comparable to cellular membranes, PS on WNV and DENV is markedly reduced. These findings explain why only ZIKV can bind GAS6 and provide insights into a novel mechanism by which closely related flaviviruses differentially utilize cellular entry factors. IMPORTANCE: Among flaviviruses, Zika virus uniquely causes microcephaly and congenital defects. While no flavivirus-specific entry receptors have been identified, they commonly take advantage of phosphatidylserine (PS) receptors to enter cells. Our previous studies revealed that Zika virus uniquely utilizes AXL, found in immune-privileged sites, such as the brain and placenta, via binding to its ligand, GAS6. Our current study shows that despite being produced from the same cells, the Zika virus has substantially higher PS content than closely related dengue and West Nile viruses, which likely explains the Zika virus's unique ability to bind GAS6. These findings provide insight into how closely related flaviviruses can vary substantially in their use of cellular entry factors, potentially contributing to the distinct diseases they cause.

20 November 2025 in bioRxiv
Verified
Preprint
Open access
HMHuihui Mou
Huihui Mou
BGBo Gao
Bo Gao
GYGang Ye
Gang Ye
LZLizhou Zhang
Lizhou Zhang
DSDivyasha Saxena
Divyasha Saxena
HCHyeryun Choe
Hyeryun Choe
The SARS-CoV-2 spike protein binds its receptor ACE2 to initiate target-cell infection. To engage ACE2, at least one of the three receptor-binding domains (RBDs) of the spike must adopt the up orientation. Here we describe S22, a potent, bioavailable, and non-toxic inhibitor of BA.2 and all subsequent Omicron variants. Cryo-EM analyses showed that S22 assembled as a trimer in a previously uncharacterized pocket of the spike apex, stabilizing all three RBDs in the down orientation, thereby preventing ACE2 association. Binding studies, especially those using mixed S22-sensitive and -resistant spikes, imply a cooperative assembly of three S22 molecules with three RBDs, resulting in an unusually slow S22 off-rate. Consistent with its slow dissociation and favorable pharmacokinetics, S22 suppressed viral replication 100-fold in the lungs of XBB.1.5-infected mice. Thus, S22 potently inhibits Omicron entry through a distinct mechanism whereby a small compound assembles cooperatively as a trimer to stabilize spike in an inactive conformation.

19 November 2024 in Journal of Virology
Verified
Journal Article
Open access
LZLizhou Zhang
Lizhou Zhang
CKClaire E. Kitzmiller
Claire E. Kitzmiller
ARAudrey S. Richard
Audrey S. Richard
SPSonam Popli
Sonam Popli
HCHyeryun Choe
Hyeryun Choe
T-cell immunoglobulin and mucin (TIM) family proteins facilitate the clearance of apoptotic cells, are involved in immune regulation, and promote infection of enveloped viruses. These processes are frequently studied in experimental animals, such as mice or rhesus macaques, but functional differences among the TIM orthologs from these species have not been described. Previously, we reported that while all three human TIM proteins bind phosphatidylserine (PS), only human TIM1 (hTIM1) binds phosphatidylethanolamine (PE), and that this PE-binding ability contributes to both phagocytic clearance of apoptotic cells and viral infection. Here, we show that rhesus macaque TIM1 (rhTIM1) and mouse TIM1 (mTIM1) bind PS but not PE, and that their inability to bind PE makes them less efficient than hTIM1. We also show that alteration of only two residues of mTIM1 or rhTIM1 enables them to bind both PE and PS, and that these PE-binding variants are more efficient at phagocytosis and mediating viral entry. Further, we demonstrate that the mucin domain also contributes to the binding of the virions and apoptotic cells, although it does not directly bind phospholipid. Interestingly, contribution of the hTIM1 mucin domain is more pronounced in the presence of a PE-binding head domain. These results demonstrate that rhTIM1 and mTIM1 are inherently less functional than hTIM1, owing to their inability to bind PE and their less functional mucin domains. They also imply that mouse and macaque models underestimate the activity of hTIM1. IMPORTANCE: We previously reported that human T-cell immunoglobulin and mucin protein 1 (TIM1) binds phosphatidylethanolamine (PE) as well as phosphatidylserine (PS), and that PE is exposed on the apoptotic cells and viral envelopes. Moreover, TIM1 recognition of PE contributes to phagocytic clearance of apoptotic cells and virus uptake. Here, we report that unlike human TIM1, murine and rhesus TIM1 orthologs bind only PS, and as a result, their ability to clear apoptotic cells or promote virus infection is less efficient. These findings are significant because they imply that the activity of TIM1 in humans is greater than what the studies conducted in common animal models would indicate.

3 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
LZLizhou Zhang
Lizhou Zhang
KMKunal More
Kunal More
AOAmrita Ojha
Amrita Ojha
CJCody Jackson
Cody Jackson
BQBrian Quinlan
Brian Quinlan
HCHyeryun Choe
Hyeryun Choe
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4°C. Moreover, Pfizer-BioNTech’s 5’ UTR and Moderna’s 3’ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.